Review

Curcumin as a natural remedy for atherosclerosis: a pharmacological review

Laxman Singh 1, Shikha Sharma 2, Suowen Xu 3,*, Devesh Tewari 2,*, Jian Fang 4,*

1 Centre of Biodiversity Conservation & Management, G.B.Pant National Institute of Himalayan Environment, Kosi-Katarmal, Almora, Uttarakhand, India; laxmansingh_13@yahoo.com

2 School of Pharmaceutical Sciences, Lovely Professional University, Phagwara-144411, Punjab, India; shikhasharma22012@gmail.com (S.S.); dtewari3@gmail.com (D.T.)

3 Department of Endocrinology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230037, China; sxu1984@ustc.edu.cn (S.X)

4 Department of Pharmacy, Huadu District People’s Hospital, Southern Medical University, Guangzhou, China; lifegz@qq.com (J.F)

* Correspondence: lifegz@qq.com; sxu1984@ustc.edu.cn; dtewari3@gmail.com

Abstract: Curcumin ( diferuloyl methane), a natural polyphenolic compound, is prevalent in Curcuma longa L. rhizomes, showing strong anti-oxidant, anti-inflammatory, anticancer and anti-atherosclerotic properties. Atherosclerosis is an umbrella term for a series of degenerative and hyperplastic lesions such as thickening or sclerosis in large and medium-sized artery walls that decrease vascular-wall elasticity and lumen diameter. The atherosclerotic cerebro-cardiovascular disease has become a major concern for human health in recent years. Curcumin concoction has been shown in studies to modulate several important signalling pathways related to cellular growth, proliferation, cholesterol homeostasis, inflammation, and transcriptions, among other things. Here, we provide an overview of Curcumin’s underlying mechanism of action and protective effects against atherosclerosis.

Keywords: Curcumin; atherosclerosis; pharmacology; therapeutics

1. Introduction

Atherosclerosis is a common cause of cerebro-cardiovascular disease and is an age-related chronic large-artery disease that tends to occur in adult and aged patients [1]. The pathogenesis of atherosclerosis is extremely multifaceted. Numerous investigations have highlighted hyperlipidemia, diabetes, smoking, and hypertension, etc. to endorse oxidative stress causing damage to vascular endothelial cells, infiltration of low-density lipoprotein into the sub-endothelial spaces, monocyte chemotaxis and aggregation below the endothelium, and platelet activation leading to chronic inflammatory responses in vascular walls [2–5]. Atherosclerosis is the pathological basis for many cerebro-cardiovascular diseases and acute cerebro-cardiovascular events such as myocardial infarction and ischemic stroke, making it a serious public health concern. [6,7] Anti-arteriosclerotic traditional Chinese medicines are widely used in Chinese clinical practice with a good safety profile and lasting efficacy [8,9]. Studies have found that many traditional Chinese medicines such as turmeric and ginseng have anti-atherosclerotic effects [10,11].
Turmeric prepared from the dried rhizome of Curcuma longa (family-Zingiberaceae) was enriched with numerous proven bioactivities and therapeutic applications. The roots of turmeric contain curcumin that has been used as a traditional drug to increase blood circulation and remove stasis [12]. Curcumin has lipid-lowering, anti-oxidative, anti-inflammatory, and anti-infective effects [13–15]. There is growing evidence that curcumin can regulate different signalling molecules to restrain the progression and development of atherosclerosis [16]. Similarly, it is also known to regulate inflammatory responses by inhibiting nuclear factor kappa B (NF-κB) expression in atherosclerotic plaques of aortic walls in domestic rabbits and alleviate the severity of atherosclerosis [16].

The mechanistic function of curcumin against atherosclerosis is due to its anti-inflammatory and anti-oxidative effects, inhibition of vascular smooth muscle cell (VSMC) proliferation and migration. Firstly, inflammation is involved in the entire process of atherosclerosis progression [17]. According to previous research, curcumin affects inflammatory cells and factors such as inflammation-related enzymes to exert its anti-inflammatory effects. [18,19]. Likewise, it blocks NF-κB signalling to diminish the production of vascular cell-adhesion molecules and inhibit interactions between leukocytes and endothelial cells [20]. Secondly, oxidative stress is a prominent marker molecule that initiates the development of atherosclerosis [21]. Oxidized low-density lipoprotein (oxLDL) is the central link in atherosclerosis [22]. Curcumin decreases the sensitivity of low-density lipoprotein (LDL) towards being oxidized, and thus decreases the amount of oxidized product to interact with the oxidized low-density lipoprotein receptor 1 (LOX-1) [23]. Curcumin can also down regulate inducible nitric oxide synthase activity to inhibit nitro-/oxidative-stress [24]. Thirdly, VSMC proliferation and migration to the intima causes intimal thickening in atherosclerosis. Specifically, neointimal responses associated with artery damage cause proliferation, migration, and collagen synthesis in VSMCs that may increase the susceptibility of blood vessels towards atherosclerosis [25]. Curcumin can increase PPAR-γ activity to inhibit the proliferation of VSMCs [26].

Additionally, epidemiological studies highlight that human cytomegalovirus (HCMV) infection is intimately coupled with the progression and development of atherosclerosis [27]. HCMV gene product can enter and damage vascular endothelial cells and alter their proliferation [28]. Oral administration of curcumin in ApoE-/-mice inhibits HCMV-protein expression and improves the cellular microenvironment in the host, thereby effectively preventing the development of atherosclerotic lesions [29].

2. Atheroprotective effects of curcumin in vitro

The potential of curcumin in countering the force against various ailments has been widely studied, including atherosclerosis. Atherosclerosis is a chronic inflammatory disease resulting from arterial wall injuries; sustained due to dyslipidemia, diabetes, hypertension, etc. that leads to macrophage and VSMC-derived foam cell formation, endothelial cell dysfunction, and immune cell activation and platelet activation and thrombus formation [30, 31, 32, 33]. Several studies have demonstrated curcumin’s potent therapeutic potential in preventing foam cell formation, modulating macrophage polarization, tuning cholesterol efflux, and regulating pro-inflammatory response [16, 34, 35, 36, 37, 38]. The anti-atherosclerotic property of curcumin is through suppressing macrophage polarization (M1 to M2) [39] or by inducing M2 polarization via IL-4 and/or IL-13 secretion in macrophages [40]. Similarly, convincing evidence suggests that curcumin when in action against macrophages treated with oxLDL, upregulates the expres-
Expression of thrombospondin-4 (THBS-4) [36] and modulates chemoattractant protein-1 (MCP-1) responsible for anti-inflammatory response [41]. The molecular targets of curcumin exerting anti-atherosclerotic effects involve upregulation of miR-126, which, in a way, further inhibits signal transduction and PI3K/AKT and JAK2/STAT5 activation [42]. Other targets include NF-κB inhibition in the M1 macrophage phenotype or by IκBα activation and, lastly, promoting M2 phenotype via PPAR-γ activation. Further, curcumin inhibits TLR4 toll like receptor-4 (TLR4), MAPK and NF-κB signalling in macrophages and VSMCs [43] (Table 1).

### Table 1. Evidence highlighting the potent potential of curcumin against atherosclerosis is confirmed by in vitro studies.

| Experimental model                  | Curcumin concentration used | Outcomes and possible mechanisms of action                                                                 | References |
|-------------------------------------|----------------------------|-------------------------------------------------------------------------------------------------------------|------------|
| U937 monocytes cell-culture        | 0.01–1 µM                  | -Inhibits lipid peroxidation and inflammatory cytokine production at high glucose concentration            | [44]       |
| HMEC-1 cells                       | 0.1–10 µM                  | -Reduce cell migration, viability, and repress MMP-2, MMP-9, and VEGF expression                          | [42]       |
|                                     |                            | -Upregulates miR-126 expression and inhibits PI3K/AKT and JAK2/STAT5 signal transduction                   |            |
| ANA-1 mouse macrophage cell line   | 5–25 µM                    | -Curcumin at all concentration significantly decreased THBS-4 expression as induced by oxLDL             | [36]       |
| RAW 264.7 murine macrophages.      |                            | -Inhibits cell formation and CD36 expression level via p38 MAPK phosphorylation inhibition               | [34]       |
| H9c2 rat cardiac myoblasts         | 5–40 µM                    | -Activates p38-MAPK and JNKs, signalling pathways                                                      | [36]       |
|                                     |                            | -Promote apoptosis by chromatin condensation                                                           |            |
| Human monocytic THP-1 cell line    | 7.5 – 30 µM                | -Inhibits M1 macrophage polarization, cytokine production (IL-6, IL-12B, TNF-α) and decrease in TLR-4 expression | [43]       |
|                                     |                            | -Inhibits ERK, JNK, p38 and NF-Kb phosphorylation, exerting anti-inflammatory and anti-atherosclerosis activity |            |
| Human THP-1 cell line              | 5 – 20 µM                  | -Reduce influx of oxLDL in THP-1 cells                                                                   | [9]        |
|                                     |                            | -Suppress CD36 and aP2 expression                                                                      |            |
| RAW264.7 macrophage                | 6.25 and 12.5 µM/L         | -Increase cholesterol via Apo-A1 and HDL in M1 cells                                                  | [37]       |
|                                     |                            | -Reduced ox-LDL induced cytokine production as well as M1 cell apoptosis                               |            |
|                                     |                            | -Upregulates CD36 and ABCA1 expression in M1 macrophages                                              |            |
| Ba/F3 cells                        | 10–20 µM                   | -Inhibit TLR4 dimerization at the receptor level                                                        | [45]       |
| Cell Type                                      | Concentration | Effect                                                                                           | Reference |
|-----------------------------------------------|---------------|-------------------------------------------------------------------------------------------------|-----------|
| RAW264.7 macrophages                          | 6.25-25 μM    | - Inhibits activation of MyD88 and TRIF-dependent pathways, thereby blocks NF-κB and IRF3 signalling | [46]      |
| Raw264.7 macrophage cell line                | 6.25-50 μM    | - Inhibit M1 phenotype markers expression (i.e. iNOS, IL-1β, IL-6, and MCP-1) and up regulates IκBα expression |          |
| Murine macrophage RAW 264.7 cells            | 6.25, and 25 nM | - Repress titanium (Ti) particle-induced inflammation via modulating macrophage M1 to M2 polarization | [34]      |
| RAW 264.7 cells                               | 8-128 μM      | - Inhibits lipid accumulation and MCP 1, TNF α, IL 6 production                                 | [47]      |
| Mouse peritoneal macrophages                 | 10-50 μM      | - Curcumin significantly reduced TLR4 expression and inhibited NF-Kb activation                  | [16]      |
| Human THP1 cells                             | 20 - 40 μM    | - Curcumin inhibit HIF-1α induced apoptosis and inflammation of macrophages via ERK signalling pathways | [48]      |
| Bovine aortic endothelial cells (BAECs)      | 5 μM-15 μM    | - When stimulated with TGF-β, curcumin inhibits the expression of ET-1mRNA in BAECs, which may influence the formation of atherosclerotic plaques | [49]      |
| Raw 264.7 cells                              | 0.1 -30 μM    | - Repress IL-1β, IL-6, and TNF-α production                                                      | [50]      |
| Human monocyte cell line THP-1               | 0 - 50 μM     | - Curcumin attenuates MMP-9 and EMMPRIN expression via down regulation of NF-κb and p38 MAPK signaling | [51]      |
| Human monocytic cell line THP-1              | 0 to 100 μM   | - Curcumin inhibits MMP-9 and EMMPRIN expression via AMPK and PKC pathway down-regulation      | [52]      |
| Human monocytic cell line THP-1              | 10–20 μM      | - Inhibit the PKC-δ/NADPH oxidase/ROS signaling and suppress matrix invasion                    | [53]      |
| Human monocytic THP-1 cells                  | 0–50 μM       | - Suppress TLR4/MyD88/NF-κb and P2X7R signaling, and inhibit inflammasome expression            | [54]      |
| THP1-derived macrophage foam cells           | 0-80 μM       | - Promote cholesterol efflux via increased ABCA1 expression via AMPK-SIRT1-LXRα signalling     | [38]      |
| Human monocyctic cell line THP-1             | 5.0 μg/mL     | - Hydroxyl acylated curcumin under                                                               | [55]      |
| Cells                             | Concentration | Effects and Mechanisms                                                                 | References |
|----------------------------------|---------------|--------------------------------------------------------------------------------------|------------|
| THP-1 macrophages                | Low intensity ultrasound | Increased apoptosis and necrotic effect on THP-1 macrophages, indicating sonodynamic therapy for atherosclerosis | [56]       |
| VSMCs                            | 5-30 µM       | - Suppress oxLDL induced MCP-1 expression via p38 MAPK and NF-kB signaling            | [55]       |
| H9c2 embryonic rat heart derived cells | 5–15 µM      | - Enhance DOX-induced cells apoptosis via Bcl-2 repression and increasing expression of caspase-8 & 9 | [58]       |
| VSMCs                            | 5- 30 µM      | - Inhibits overexpression of MCP-1, TNF-α, NO and ROS production                     | [57]       |
| VSMCs                            | 5- 30 µM      | - Suppresses TLR4 activation and inhibits ERK1/2 and p38 MAPK phosphorylation         | [59]       |
| Raw264.7 cells                   | 0–40 µM       | - Inhibit MCP-1 production via the JNK and NK-kB signalling                           | [60]       |
| 3T3-L1 fibroblast cells          | 0–30 µM       | - Enhance cholesterol efflux via activating the LXR-α – ABCA1/SR-BI pathway          | [61]       |
| VSMCs                            | 1.25 - 5 µM   | - Inhibits CRP protein production by modulating ROS-ERK1/2 signalling                | [62]       |
| Endothelial cells                | 10⁻⁵mol/L     | - Inhibit CD40 expression and inflammatory activity via miR-590-3p-dependent pathway | [63]       |
| Cultured porcine coronary artery rings | 5 µmol/L   | - Blocks superoxide anion production mediated by eNOS down-regulation and reverses endothelial dysfunction | [64]       |
| HUVEC cells                      | 1, 10, 100 µM | - Reduce E and P-selectins expression and monocytes adhesion as induced by PM10 (3 µg/cm²) and TiO2-NPs (10 µg/cm²) | [65]       |
| HUVEC cells                      | 25 µM         | - Attenuate oxidative stress activation as a result of PM10 particles and TiO2-NPs on endothelial cells | [66]       |
| HUVEC cells                      | 1- 25 µM      | - Inhibits COX-2 expression and prostaglandin production                             | [67]       |
|                                  |               | - Inhibits phosphorylation of PKC, p38 MAPK, and cAMP response triggering COX-2 expression |            |
|                                  |               | - Suppressed the expression profile of ROS species, LOX-1 receptor and adhesion molecules (VCAM-1 and ICAM-1) | [68]       |
|                                  |               | - Inhibits IκBα degradation and nuclear NFκB translocation                           |            |
| Cells          | Concentration (µM) | Effects                                                                                   | Reference |
|---------------|--------------------|------------------------------------------------------------------------------------------|-----------|
| HUVEC cells   | 2.5 - 100          | - Inhibits adhesion molecules and E-selectin expression that reconcile monocyte adhesion and endothelial migration | [67]      |
|               |                    | - TLR2 and TLR4 receptors that bind HMGB1 and cause an inflammatory response are downregulated. |           |
| HUVEC cells   | 3 - 30             | - Inhibits NF-κB activation via TNF-α                                                   | [68]      |
|               |                    | - Suppress intracellular ROS production, monocyte adhesion, JNK, p38 and STAT-3 phosphorylation |           |
|               |                    | - Attenuates expression profile of ICAM-1, MCP 1, and IL 8 at both mRNA and protein level |           |
| VSMCs         | 20 - 40            | - Diminish phosphorylation of p-RhoA/p-MEK1/2 and NF-κB signaling                          | [69]      |
| VSMCs         |                    | - Activates miR-22/SP1 signalling pathway and prevents Proliferation and migration of VSMCs | [70]      |
| VSMCs         | 12.5 - 50          | - Inhibits cholesterol accumulation via activating caveolin-1 expression that in turn negatively regulates SREBP-1 and prevents nuclear translocation | [71]      |
| HUVEC cells   | 0.5 – 2            | - Inhibited HCMV replication and proliferation                                           | [29]      |
|               |                    | - Reduced intracellular ROS production, and diminished inflammatory cytokine production |           |
|               |                    | - Down-regulates HMGB1-TLR-NF-κB signalling                                               |           |
| VSMCs         | 10 - 20            | - Reduces NO production by inhibiting IL-6 and TNF-expression                            | [34]      |
|               |                    | - Upregulate PPAR-γ activity and attenuates VSMCs proliferation                          |           |
| VSMCs         | 20                 | - Inhibits cell migration by negatively regulating NLRP3 expression via NfκB-mediated response and reduces IL-1β concentration | [26]      |

**Abbreviations:**

- **HMEC-1**: Human micro-vascular endothelial cell
- **PARP**: Poly(ADP-ribose) polymerase
- **MMR**: Macrophage mannose receptor
- **Arg-1**: Arginase-1
- **HIF-1a**: Hypoxia-inducible factor 1α
- **TGF-β**: Transforming growth factor beta
- **AMPK**: AMP-activated protein kinase
- **PKC**: Protein Kinase C
- **DOX**: Doxorubicin
- **ET-1**: Endothelin-1
- **TGF-β**: Transforming growth factor β
- **PAR**: Proliferator-activated receptor
- **LXR**: Liver X receptor
- **SR-BI**: Scavenger receptor class B type 1
- **JAKs**: Janus activated kinases
- **iNOS**: Inducible nitric oxide synthase
- **MyD88**: Myeloid differentiation factor 88
- **P2X7R**: Purinergic 2X7 receptor
- **PKC**: Protein kinase C
- **AD**: Aldosterone
- **CRP**: C-reactive protein
- **HUVEC**: Human umbilical vein endothelial cells
- **LOX-1**: Lectin-like oxidized VLDL receptor
LDL receptor-1, TEM- Trans-endothelial migration, HMGB1- High mobility group box-1 , MEK ½- mitogen-activated protein kinase kinase ½, JNK- c-Jun N-terminal Kinase

TLR4, an important signalling receptor, has been actively reported in the pathogenesis of plaque formation and atherosclerosis development [72]. Furthermore, TLR4 activates a variety of signal transduction molecules as well as transcription factor activation. The important one being NF-xB and MAPK activation, that triggers nuclear transduction that simultaneously propels gene expression profile of inflammatory reaction. Amplified expression profile increases ROS production and inflammatory molecules, which cause the initiation of atherogenesis, finally destabilising atherosclerotic plaques [16]. Reports on curcumin supplementation foster negative regulation not only on TLR receptor but also on nuclear transduction molecules and inflammatory cytokines (TNF-α, IL-1β, VCAM-1, ICAM 1, etc.) are presented [73] (Figure. 1).

Likewise, curcumin stalls ligand-induced and ligand-independent dimerization at the receptor level. LPS-induces activation of both MyD88-and TRIF-dependent signalling via TLR4 receptor. Upon curcumin supplementation and inhibition of TLR4 receptor, further molecular docking between receptor and NF-kB and IRF3 stimulation is examined [45]. In a similar fashion, curcumin inhibited the NOD-like receptor (NLR) family,
the pyrin domain containing 3 (NLRP3) inflammasome via suppressing TLR4/MyD88/NF-kB, phosphorylation level of IkB-α and purinergic 2X7 receptor (P2X7R) pathways in Phorbol 12-myristate 13-acetate (PMA)-induced macrophages [54]. NLRP3 inflammasome is composed of a multiprotein complex having caspase and caspase 1 protein complex for apoptosis [74]. On NLRP3 complex stimulation, caspase-1 is activated that cleaves off the pro-forms of interleukin (IL)-1β and IL-18 into their mature forms. Once in fully mature form, IL-1β (a primary pro-inflammatory cytokine) mediates the development of atherosclerosis. Curcumin also inhibits cell migration in VSMCs by negatively regulating NLRP3 expression via an NF-B-mediated response and decreasing IL-1 concentration [54], halting atherosclerosis progression.

Likewise, curcumin supplementation in VSMCs markedly reduces inflammatory responses induced by LPS via TLR4 activation. This stimulation significantly increases phosphorylation of IkBα, NF-κB (p65) and MAPKs [58]. Concurrently, this increases the inflammatory cytokine expression profile of TLR4, MCP-1, iNOS, TNF-α, and NO production. In addition, Meng et al. (2013) [58] established curcumin supplementation inhibits TLR4 activation ERK1/2 and p38 MAPK phosphorylation and prevents NF-κB nuclear translocation that mediates ROS production. Thus, inhibition of the expression profile may reduce atherosclerotic plaque formation, and reduce plaque infiltration and progression. More recently, Zhang et al. [61] have shown that curcumin inhibited aldosterone-induced production of CRP in VSMCs by reducing ROS production via limiting aberrant activation of the ERK1/2 signal pathway.

LDL is another important pathological stimuli that contribute to atherosclerotic lesions. ROS modifies LDL, thereby producing Ox-LDL. An increase in Ox-LDL concentration in plasma has long been accredited as a key factor resulting in atherosclerosis development. Ox-LDL, instead of binding to LDL receptor, binds to scavenger receptors (SRs). The major SRs receptor is a differentiation 36 (CD36) cluster that recognizes ox-LDL [75]. ox-LDL on binding with CD36 receptor activates PPAR-Y[76]. PPAR-Y, once activated, dimerizes with the retinoid X receptor (RXR) and triggers PPAR-response element (PPRE) containing a gene which ultimately increases CD36 expression, resulting in more ox-LDL influx [77]. Cholesterol accumulation in macrophages results in foam cell formation and fatty streak development. Other channels/receptors used by macrophages to influx ox-LDL-related receptors include: SR-AI/II, SRBI, CD36, LOX-1, and TLRs. In contrast to this, various efflux transporters play an active role via ATP-binding cassette (ABC) transporters ABCA1, ABCG1, and SR-BI to overturn cholesterol transport from macrophages [78]. Fatty acid-binding protein (FABP)-4 or adipocyte protein 2 (aP2) coordinates cholesterol trafficking (efflux) but is also known to activate an inflammatory response. Lack of aP2 protein complex changes the cholesterol composition in macrophages, which concurrently amplify CD36 expression and enhance oxLDL influx [79]. This creates a diseased state whereby macrophages induce the release of IL-1β, TNFα, ROS, and metalloproteases coupled with the development of inflammation, cell migration, and plaque formation (Figure. 1). Hence, reducing or total inhibition of aP2 and CD36 expression might offer protective and remedial promise to atherosclerosis development.

Several lines of experimental evidence have highlighted curcumin’s potent anti-atherogenic effects over the years (Table 1). Zhou et al. (2014) [36] demonstrated curcumin reduced the expression profile of oxLDL-induced Thrombospondins-4 (THBS-4). THBS-4 was reported to influence important cellular responses like cell migration, proliferation and adhesion, leading to atherogenesis progression [80]. Curcumin further in-
hibits p38 MAPK activation; reduces PPAR-Ƴ and CD36 expression in oxLDL-treated macrophage, resulting in decreased foam cell formation [76]. In human umbilical vein endothelial cells (HUVECs), curcumin inhibits ROS production, inhibits LOX-1 and NF-κB expression, inhibits adhesion (VCAM-1 and ICAM-1) molecules and promotes NO production [66]. Recent studies also suggest that curcumin could reduce oxidative stress, ER stress and inflammatory response induced by acrolein (a toxin from tobacco smoke) and cytomegalovirus (CMV) infection in human endothelial cells [29,65]. The anti-inflammatory mechanism of curcumin is through inhibiting COX-2 expression and prostaglandin production via reducing phosphorylation of PKC, p38 MAPK, and cAMP response element-binding protein as well as HMGB1-TLRS-NF-κB signalling pathway [29,65]. The broad anti-inflammatory effects of curcumin underline its reported effects on improving flow-mediated dilation in human subjects [81].

Atheroprotective effects of curcumin in vivo

Numerous lines of experimental evidence in vivo models advocate the high relevance of curcumin in reducing the cardiovascular risk associated with atherosclerosis. Ramírez-Tortosa et al. (1999) [10] studied ethanolic rhizome extract on LDL oxidation and plasma lipids concentration in rabbits. Atherosclerosis was induced by feeding with a diet that contains 95.7% standard chow, 3% lard and 1.3% cholesterol. Two groups received extracted doses of 1.66 (group A) and 3.2 (group B) mg/kg body weight of the three groups, while the third group served as control. Lipid peroxidation in high extract dosage (group B) was highest i.e. 10.48 ± 2.66 mg/dl, then low extract dosage (group A) (9.20 ± 2.10) and control (8.47 ± 1.14 mg/dl). Total plasma cholesterol was significantly lower in group A (1495± 174 mg/dl) and group B (1489 ± 227mg/dl) when compared to the control (2589± 160 mg/dl). Moreover, group A had lower levels of cholesterol (1495± 174 mg/dl), phospholipids (938 ± 155 mg/dl) and triglycerides (190±12 mg/dl) in LDL than group B of extract featuring phospholipids (1084± 61 mg/dl), and triglycerides (198±23 mg/dl). The results highlight C. longa extract administration in decreasing lipid peroxidation. In conclusion, usage of this extract was thought to provide some relief against atherosclerosis development.

Similarly, Li et al. (2015) [82] established a heart disease model that studied the permeability, protein expression and therapeutic potential of curcumin extract in treating male Wistar rat coronary heart disease (CHD). Atherosclerosis was induced by feeding with a diet enriched with high-fat content for 12 weeks along with vitamin D3 injection intraperitoneally. Once atherosclerosis was developed, curcumin (100 mg/kg d) was provided for four weeks of experimentation. Upon completion, the heart was finally dissected, and the coronary artery was obtained. Using the immunofluorescence method, pathological changes in endarterium permeability were compared between blank control, treatment and model control group. Fluorochrome permeability was highest in the model control group, then the treated group, and least in blank control.

Similarly, changes in MMP-9 and CD40L was detected using Western blotting assay, wherein MMP-9 and CD40L were significantly higher than treated and control. Similar findings were obtained for the expression profile of serum TNF-α and CRP using ELISA. The results highlight rat CHD might be due to upregulation of MMP-9, CD40L, TNF-α and CRP protein and its permeability, which in the treated group was counter checked/inhibited by curcumin placebo.
Likewise, Zhang et al. (2017) [16] studied the pathogenesis of atherosclerosis via suppressing TLR4 using curcumin in ApoE−/−mice. The treated mice were kept on curcumin extract (0.1% w/w) for 16 weeks. The result highlights a significant reduction in TLR4 expression, IL-1β, TNF-α, VCAM-1, ICAM-1, and NF-κB activity. In addition, it inhibited macrophage infiltration, atherosclerotic plaques and lesions development in aortic tissues.

In addition, Hasan and coworkers [9] studied the effect of Curcumin supplementation (500; 1000; 1500 mg/kg diet) on atherosclerosis in Ldlr−/−mice for 16 weeks. The finding highlight Curcumin dose-dependently reduced uptake of oxLDL in THP-1 cells and modulated lipid metabolism. At medium doses of 500-1000 mg/kg diet, curcumin effectively reduced fatty streak formation and inhibited inflammatory cytokine production. In addition, a high dose (1500mg/kg diet) of curcumin, suppressed the progression of steatohepatitis, reduced tissue fibrosis, and preserved glycogen levels in the liver. As a result of the findings, curcumin at a medium dosage was most effective in suppressing aP2 and CD36 expression and preventing atherosclerosis. Human cytomegalovirus (CMV) infection is an important risk factor for atherosclerosis, and curcumin has demonstrated protective effects against HCMV-infection. In a recent model of atherosclerosis in ApoE−/−mice infected with mouse CMV, curcumin inhibited the replication and proliferation of CMV, reduced lipid profile (TC, TG, and LDL), and aortic lesion area [29], indicating that the anti-atherosclerotic effects of curcumin is also related to its anti-infectious effects.

More recently, oral administration of curcumin has been reported to reduce fatty streaks and aortic lesions in cholesterol-fed rabbits. Mechanistic studies revealed that curcumin increased antioxidant capacity, lowered the serum levels of TC, TG, and LDL, and reduced the levels of pro-inflammatory markers (CRP, ICAM1, and VCAM1). The lipid-modulatory effects of curcumin are possibly related to decreased expression of PCSK9. In cholesterol-fed rabbits, curcumin also exerts anti-atherosclerotic effects via increasing miR-126, thereby reducing the activation of PI3K/AKT and JAK2/STAT5 [42]. Therefore, curcumin could prevent atherosclerosis via inhibiting oxidative stress, systemic inflammation, and hypoglycemic effects [83].

Conclusion and perspectives

In conclusion, substantial experimental evidence suggests that curcumin prevents endothelial dysfunction and foam cell formation and modulates macrophage polarization and counteracts inflammatory response, supporting its potential role in anti-atherosclerosis activity. The anti-atherosclerosis property of curcumin is through suppressing inflammatory response by skewing macrophage polarization from M1 to M2 or by inducing M2 polarization through regulating TLR4/MAPK/NF-κB pathways in macrophages and secretion of interleukins (IL-4 and/or IL-13). Similarly, curcumin concurrently regulated the expression and activity of lipid transporter expression (CD36, CD38, ABCA1, aP2 etc.) for cholesterol uptake and efflux, thus maintaining cell homeostasis. In addition, Curcumin reduces ox-LDL level and oxLDL elicited pro-atherogenic events by reducing MCP-1/THBS-4 expression via the p38 MAPK and NF-κB pathways [51]. Likewise, curcumin suppresses TLR4 expression and macrophage infiltration in aorta tissue and protects against atherosclerosis plaque formation [16]. Additional studies are required to improve or add meaningful insights into our understanding of the mechanism of the action of curcumin against atherosclerosis in mice and human patients. In addition, the development of novel drug delivery systems, such as the creation of curcumin nanomicelles [84,85], is critical for improving curcumin oral bioavailability [86].
Author Contributions: Conceptualization, S.X., D.T. and J.F.; data curation, L.S., S.S., and DT; writing—original draft preparation, L.S., J.F. and D.T.; writing—review and editing, S.X., D.T., J.F.; supervision, S.X.; funding acquisition, S.X. All authors have read and agreed to the published version of the manuscript.

Funding: This study was partially supported by grants from Natural Science Foundation of China (No. 82070464).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: D.T. and S.S. express their gratitude towards Management, Senior Dean and CoD of Lovely Professional University, Punjab, India for providing necessary facilities and time to conduct the study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Hannawi, S.; Hannawi, H.; Al Salmi, I. Cardiovascular disease and subclinical atherosclerosis in rheumatoid arthritis. Hypertens. Res. 2020, 43, 982–984, doi:10.1038/s41440-020-0483-4.

2. Bi, C.; Fu, Y.; Li, B. Brain-derived neurotrophic factor alleviates diabetes mellitus-accelerated atherosclerosis by promoting M2 polarization of macrophages through repressing the STAT3 pathway. Cell. Signal. 2020, 70, 109569, doi:10.1016/j.cellsig.2020.109569.

3. Ito, K.; Maeda, T.; Tada, K.; Takahashi, K.; Yasuno, T.; Masutani, K.; Mukoubara, S.; Arima, H.; Nakashima, H. The role of cigarette smoking on new-onset of chronic kidney disease in a Japanese population without prior chronic kidney disease: Iki epidemiological study of atherosclerosis and chronic kidney disease (ISSA-CKD). Clin. Exp. Nephrol. 2020, 24, 919–926, doi:10.1007/s10157-020-01914-8.

4. Miao, J.; Zang, X.; Cui, X.; Zhang, J. Autophagy, Hyperlipidemia, and Atherosclerosis. Adv. Exp. Med. Biol. 2020, 1207, 237–264, doi:10.1007/978-981-15-4272-5_18.

5. Ye, J.; Wang, Y.; Wang, Z.; Liu, L.; Yang, Z.; Wang, M.; Xu, Y.; Ye, D.; Zhang, J.; Zhou, Q.; et al. The Expression of IL-12 Family Members in Patients with Hypertension and Its Association with the Occurrence of Carotid Atherosclerosis. Mediators Inflamm. 2020, 2020, 2369279, doi:10.1155/2020/2369279.

6. Ntaios, G.; Pearce, L.A.; Meseguer, E.; Endres, M.; Amarenco, P.; Ozturk, S.; Lang, W.; Bornstein, N.M.; Molina, C.A.; Pagola, J.; et al. Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial. Stroke 2019, 50, 3184–3190, doi:10.1161/STROKEAHA.119.025813.

7. Pomozova, T.P.; Lykov, Y. V; Komarova, I.S.; Dyatlov, N. V; Zhelnov, V. V [Clinical and laboratory features of primary acute myocardial infarction in patients with obstructive and non-obstructive coronary atherosclerosis]. Kardiologin 2019, 59, 41–51, doi:10.18087/cardio.26.240.

8. Liu, C.; Huang, Y. Chinese Herbal Medicine on Cardiovascular Diseases and the Mechanisms of Action. Front. Pharmacol. 2016, 7, 469, doi:10.3389/fphar.2016.004699. Hasan, S.T.; Zingg, J.-M.; Kwan, P.; Noble, T.; Smith, D.; Meydani, M. Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice. Atherosclerosis 2014, 232, 40–51, doi:10.1016/j.atherosclerosis.2013.10.016.

9. Ramírez-Tortosa, M.C.; Mesa, M.D.; Aguiler, M.C.; Quiles, J.L.; Baró, L.; Ramírez-Tortosa, C.L.; Martinez-Victoria, E.; Gil, A. Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. Atherosclerosis 1999, 147, 371–378, doi:10.1016/s0021-9150(99)00207-5.

10. Chan, G.H.-H.; Law, B.Y.-K.; Chu, J.M.-T.; Yue, K.K.-M.; Jiang, Z.-H.; Lau, C.-W.; Huang, Y.; Chan, S.-W.; Ying-Kit Yue, P.; Wong, R.N.-S. Ginseng extracts restore high-glucose induced vascular dysfunctions by altering triglyceride metabolism and downregulation of atherosclerosis-related genes. Evid. Based. Complement. Alternat. Med. 2013, 2013, 797310.
12. Kim, J. H., Yang, H. J., Kim, Y. J., Park, S., Lee, O. H., Kim, K. S., & Kim, M. J. Korean turmeric is effective for dyslipidemia in human intervention study. *Journal of Ethnic Foods*, 2016, 3(3), 213-221.

13. González-Ortega, L.A.; Acosta-Osorio, A.A.; Grube-Pagola, P.; Palmeros-Exsome, C.; Cano-Sarmiento, C.; García-Varela, R.; García, H.S. Anti-inflammatory Activity of Curcumin in Gel Carriers on Mice with Atrial Edema. *J. Oleo Sci.* 2020, 69, 123–131, doi:10.5650/jos.ess19212.

14. Qin, S.; Huang, L.; Gong, J.; Shen, S.; Huang, J.; Ren, H.; Hu, H. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. *Nutr. J.* 2017, 16, 68, doi:10.1186/s12937-017-0293-y.

15. Song, H.-C.; Chen, Y.; Chen, Y.; Park, J.; Zheng, M.; Surbh, Y.-J.; Kim, U.-H.; Park, J.W.; Yu, R.; Chung, H.T.; et al. GSK-3β inhibition by curcumin mitigates amyloidogenesis via TFEB activation and anti-oxidative activity in human neuroblastoma cells. *Free Radic. Res.* 2020, 1–13, doi:10.1080/10715762.2020.1791843.

16. Zhang, S.; Zou, J.; Li, P.; Zheng, X.; Feng, D. Curcumin Protects against Atherosclerosis in Apolipoprotein E-Knockout Mice by Inhibiting Toll-like Receptor 4 Expression. *J. Agric. Food Chem.* 2018, 66, 449–456, doi:10.1021/acs.jafc.7b04260.

17. Marchio, P.; Guerra-Ojeda, S.; Vila, J.M.; Aldasoro, M.; Victor, V.M.; Mauricio, M.D. Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. *Oxidative Medicine and Cellular Longevity* 2019, 1:32. https://doi.org/10.1155/2019/8563845

18. Chen, Y.-Q.; Chai, Y.-S.; Xie, K.; Yu, F.; Wang, C.-J.; Lin, S.-H.; Yang, Y.-Z.; Xu, F. Curcumin Promotes the Expression of IL-35 by Regulating Regulatory T Cell Differentiation and Restrains Uncontrolled Inflammation and Lung Injury in Mice. *Inflammation* 2020, 43, 1913–1924, doi:10.1007/s10753-020-01265-2.

19. Zhu, H.; Wang, X.; Wang, X.; Liu, B.; Yuan, Y.; Zuo, X. Curcumin attenuates inflammation and cell apoptosis through regulating NF-κB and JAK2/STAT3 signaling pathway against acute kidney injury. *Cell Cycle* 2020, 19, 1941–1951, doi:10.1080/15384101.2020.1784599.

20. Olszanecki, R.; Jawień, J.; Gajda, M.; Mateuszuk, L.; Gębska, A.; Korabiowska, M.; Chlopicki, S.; Korbut, R. Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice. *J. Physiol. Pharmacol. an Off. J. Polish Physiol. Soc.* 2005, 56, 627–635.

21. Xie, M.; Tang, Q.; Nie, J.; Zhang, C.; Zhou, X.; Yu, S.; Sun, J.; Cheng, X.; Dong, N.; Hu, Y.; et al. BMAL1-Downregulation Aggravates Porphyromonas Gingivalis-Induced Atherosclerosis by Encouraging Oxidative Stress. *Circ. Res.* 2020, 126, e15–e29, doi:10.1161/CIRCRESAHA.119.315502.

22. Libby, P.; Ridker, P.M.; Hansson, G.K. Progress and challenges in translating the biology of atherosclerosis. NATURE 2011, 473, 317-327. doi:10.1038/nature10146

23. Kattoor, A.J.; Goel, A.; Mehta, J.L. LOX-1: Regulation, Signaling and Its Role in Atherosclerosis. *Antioxidants (Basel, Switzerland)* 2019, 8, doi:10.3390/antiox8070218.

24. Boonla, O.; Kukongviriyapan, U.; Pakdeeboke, P.; Kukongviriyapan, V.; Pannangpetch, P.; Prachaney, P.; Greenwald, S.E. Curcumin improves endothelial dysfunction and vascular remodeling in 2K-1C hypertensive rats by raising nitric oxide availability and reducing oxidative stress. *Nitric oxide - Biol. Chem.* 2014, 42, 44–53, doi:10.1016/j.jniox.2014.09.001.

25. Kapakos, G.; Youreva, V.; Srivastava, A. Cardiovascular protection by curcumin: Molecular aspects. Indian Journal of Biochemistry & Biophysics 2012,49:306-315

26. Han, Y.; Sun, H.-J.; Tong, Y.; Chen, Y.-Z.; Ye, C.; Qiu, Y.; Zhang, F.; Chen, A.-D.; Qi, X.-H.; Chen, Q.; et al. Curcumin attenuates migration of vascular smooth muscle cells via inhibiting Nfκb-mediated NLRP3 expression in spontaneously hypertensive rats. *J. Nutr. Biochem.* 2019, 72, 108212, doi:10.1016/j.jnutbio.2019.07.003.

27. Horváth, R.; Cerný, J.; Benedík, J.J.; Hökl, J.; Jelinková, I.; Benedík, J. The possible role of human cytomegalovirus (HCMV) in the origin of atherosclerosis. *J. Clin. Virol.* 2000, 16, 17–24,
28. Shen, K.; Xu, L.; Chen, D.; Tang, W.; Huang, Y. Human cytomegalovirus-encoded miR-UL112 contributes to HCMV-mediated vascular diseases by inducing vascular endothelial cell dysfunction. *Virus Genes* **2018**, *54*, 172–181, doi:10.1007/s11262-018-1532-9.

29. Lv, Y.-L.; Jia, Y.; Wan, Z.; An, Z.-L.; Yang, S.; Han, F.-F.; Gong, L.-L.; Xuan, L.-L.; Ren, L.-L.; Zhang, W.; et al. Curcumin inhibits the formation of atherosclerosis in ApoE(-/-) mice by suppressing cytomegalovirus activity in endothelial cells. *Life Sci.* **2020**, *257*, 117658, doi:10.1016/j.lfs.2020.117658.

30. Förstermann, U.; Xia, N.; Li, H. Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis. *Circulation Research* **2017**, *120*, 713-735. DOI: 10.1161/CIRCRESAHA.116.309326

31. Di Pietro, N.; Formoso, G.; Pandolfi, A. Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis. *http://dx.doi.org/10.1016/j.vph.2016.05.013* 86.

32. Ahmed, S.; Khan, H.; Mirzaei, H. Mechanics insights of curcumin in myocardial ischemia: Where are we standing? European Journal of Medicinal Chemistry 2019, 183, 111658. https://doi.org/10.1016/j.ejmech.2019.111658

33. Li, C.; Miao, X.; Li, F.; Adhikari, BK.; Liu, Y.; Sun, J.; Zhang, R.; Cai, Lu.; Liu, Q.; Wang, Y. Curcuminoids: Implication for inflammation and oxidative stress in cardiovascular diseases. *Phytotherapy Research*. 2019;1–16.

34. Li, B.; Hu, Y.; Zhao, Y.; Cheng, M.; Qin, H.; Cheng, T.; Wang, Q.; Peng, X.; Zhang, X. Curcumin Attenuates Titanium Particle-Induced Inflammation by Regulating Macrophage Polarization In Vitro and In Vivo. *Front. Immunol.* **2017**, *8*, 55, doi:10.3389/fimmu.2017.00055.

35. Mottaz-Borojeni, A.A.; Banach, M.; Majeed, M.; Sahebkar, A. P5330 Evaluating lipid-lowering and anti-atherogenic effect of injectable curcumin in a rabbit model of atherosclerosis. *Eur. Heart J.* **2019**, *40*, ehz746-0299.

36. Zhou, Z.; Chen, Y.; Wang, F.; Tian, N.; Fan, C. Effect of curcumin on down-expression of thrombospondin-4 induced by oxidized low-density lipoprotein by macrophages. *Biomed. Mater. Eng.* **2014**, *24*, 181–189, doi:10.3233/BME-130798.

37. Chen, F.-Y.; Zhou, J.; Guo, N.; Ma, W.-G.; Huang, X.; Wang, H.; Yuan, Z.-Y. Curcumin retunes cholesterol transport homeostasis and inflammation response in M1 macrophage to prevent atherosclerosis. *Biochem. Biophys. Res. Commun.* **2015**, *467*, 872–878, doi:10.1016/j.bbrc.2015.10.051.

38. Lin, X.; Liu, M.-H.; Hu, H.-J.; Feng, H.; Fan, X.-J.; Zou, W.; Pan, Y.; Hu, X.; Wang, Z. Curcumin enhanced cholesterol efflux by upregulating ABCA1 expression through AMPK-SIRT1-LXRα signaling in THP-1 macrophage-derived foam cells. *DNA Cell Biol.* **2015**, *34*, 561–572, doi:10.1089/dna.2015.2866.

39. Karuppagounder, V.; Arumugam, S.; Thandavaran, R.A.; Sreedhar, R.; Giridharan, V. V; Afrin, R.; Harima, M.; Miyashita, S.; Hara, M.; Suzuki, K.; et al. Curcumin alleviates renal dysfunction and suppresses inflammation by shifting from M1 to M2 macrophage polarization in daunorubicin induced nephrotoxicity in rats. *Cytokine* **2016**, *84*, 1–9, doi:10.1016/j.cyto.2016.05.001.

40. Gao, S.; Zhou, J.; Liu, N.; Wang, L.; Gao, Q.; Wu, Y.; Zhao, Q.; Liu, P.; Wang, S.; Liu, Y.; et al. Curcumin induces M2 macrophage polarization by secretion IL-4 and/or IL-13. *J. Mol. Cell. Cardiol.* **2015**, *85*, 131–139, doi:10.1016/j.yjmcc.2015.04.025.

41. Karimian, M.S.; Pirro, M.; Majeed, M.; Sahebkar, A. Curcumin as a natural regulator of monocyte chemoattractant protein-1. *Cytokine Growth Factor Res.* **2017**, *33*, 55–63, doi:10.1016/j.cytogfr.2016.10.001.

42. Li, Y.; Tian, L.; Sun, D.; Yin, D. Curcumin ameliorates atherosclerosis through upregulation of miR-126. *J. Cell. Physiol.* **2019**, *234*, 21049–21059, doi:10.1002/jcp.28708.

43. Zhou, Y.; Zhang, T.; Wang, X.; Wei, X.; Chen, Y.; Guo, L.; Zhang, J.; Wang, C. Curcumin Modulates Macrophage Polarization Through the Inhibition of the Toll-Like Receptor 4 Expression and its Signaling Pathways. *Cell. Physiol. Biochem. Int. J.* **2015**, *36*, 631–641, doi:10.1159/000430126.

44. Jain, S.K.; Rains, J.; Croad, J.; Larson, B.; Jones, K. Curcumin supplementation lowers TNF-alpha, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-alpha, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. *Antioxid. Redox Signal.* **2009**, *11*, 241–249, doi:10.1089/ars.2008.2140.

45. Youn, H.S.; Saitoh, S.I.; Miyake, K.; Hwang, D.H. Inhibition of homodimerization of Toll-like receptor 4 by curcumin. *Biochem. Pharmacol.* **2006**, *72*, 62–69, doi:10.1016/j.bcp.2006.03.022.
46. Chen, F.; Guo, N.; Cao, G.; Zhou, J.; Yuan, Z. Molecular analysis of curcumin-induced polarization of murine RAW264.7 macrophages. *J. Cardiovasc. Pharmacol.* **2014**, *63*, 544–552, doi:10.1097/FJC.000000000000079.

47. Wang, J.; Kang, Y.-X.; Pan, W.; Lei, W.; Feng, B.; Wang, X.-J. Enhancement of Anti-Inflammatory Activity of Curcumin Using Phosphatidylserine-Containing Nanoparticles in Cultured Macrophages. *Int. J. Mol. Sci.* **2016**, *17*, doi:10.3390/ijms17060969.

48. Ouyang, S.; Yao, Y.-H.; Zhang, Z.-M.; Liu, J.-S.; Xiang, H. Curcumin inhibits hypoxia inducible factor-1α-induced inflammation and apoptosis in macrophages through an ERK dependent pathway. *Eur. Rev. Med. Pharmacol. Sci.* **2019**, *23*, 1816–1825, doi:10.26355/eurrev_201902_17145.

49. Keshavarz, Z.; Kheirollah, A.; Ghaffari, M.-A.; Babahamadi-Rezaei, H. Curcumin Inhibited Endothelin-1 mRNA Expression Induced by TGF-β in Bovine Aortic Endothelial Cell. *Jundishapur J. Nat. Pharm. Prod.* **2019**, *14*.

50. Ameruoso, A.; Palomba, R.; Palange, A.L.; Cervadoro, A.; Lee, A.; Di Mascolo, D.; Decuzzi, P. Ameliorating Amyloid-β Fibrils Triggered Inflammation via Curcumin-Loaded Polymeric Nanoconstructs. *Front. Immunol.* **2017**, *8*, 1411, doi:10.3389/fimmu.2017.01411.

51. Cao, J.; Ye, B.; Lin, L.; Tian, L.; Yang, H.; Wang, C.; Huang, W.; Huang, Z. Curcumin Alleviates oxLDL Induced MMP-9 and EMMPRIN Expression through the Inhibition of NF-κB and MAPK Pathways in Macrophages. *Front. Pharmacol.* **2017**, *8*, 62, doi:10.3389/fphar.2017.00062.

52. Cao, J.; Han, Z.; Tian, L.; Chen, K.; Fan, Y.; Ye, B.; Huang, W.; Wang, C.; Huang, Z. Curcumin inhibits EMMPRIN and MMP-9 expression through AMPK-MAPK and PKC signaling in PMA induced macrophages. *J. Transl. Med.* **2014**, *12*, 266, doi:10.1186/s12967-014-0266-2.

53. Huang, S.-L.; Chen, P.-Y.; Wu, M.-J.; Tai, M.-H.; Ho, C.-T.; Yen, J.-H. Curcuminoids Modulate the PKCδ/NADPH Oxidase/Reactive Oxygen Species Signaling Pathway and Suppress Matrix Invasion during Monocyte-Macrophage Differentiation. *J. Agric. Food Chem.* **2015**, *63*, 8838–8848, doi:10.1021/acs.jafc.5b04083.

54. Kong, F.; Ye, B.; Cao, J.; Cai, X.; Lin, L.; Huang, S.; Huang, W.; Huang, Z. Curcumin Represses NLRP3 Inflammasome Activation via TLR4/MyD88/NF-κB and P2X7R Signaling in PMA-Induced Macrophages. *Front. Pharmacol.* **2016**, *7*, 369, doi:10.3389/fphar.2016.00369.

55. Zheng, L.; Sun, X.; Zhu, X.; Lv, F.; Zhong, Z.; Zhang, F.; Guo, W.; Cao, W.; Yang, L.; Tian, Y. Apoptosis of THP-1 derived macrophages induced by sonodynamic therapy using a new sonosensitizer hydroxyl acetylated curcumin. *PLoS One* **2014**, *9*, e93133, doi:10.1371/journal.pone.0093133.

56. Zhong, Y.; Liu, T.; Guo, Z. Curcumin inhibits ox-LDL-induced MCP-1 expression by suppressing the p38MAPK and NF-κB pathways in rat vascular smooth muscle cells. *Inflamm. Res. Off. J. Eur. Histamine Res. Soc.* ... [et al.]**2012**, *61*, 61–67, doi:10.1007/s00011-011-0389-3.

57. Hosseinzadeh, L.; Behravan, J.; Mosaffa, F.; Bahrami, G.; Bahrami, A.; Karimi, G. Curcumin potentiates doxorubicin-induced apoptosis in H9c2 cardiac muscle cells through generation of reactive oxygen species. *Food Chem. Toxicol. an Int. J. Publ. Br. Ind. Biol. Res. Assoc.* **2011**, *49*, 1102–1109, doi:10.1016/j.fct.2011.01.021.

58. Meng, Z.; Yan, C.; Deng, Q.; Gao, D.; Niu, X. Curcumin inhibits LPS-induced inflammation in rat vascular smooth muscle cells in vitro via ROS-relative TLR4-MAPK/NF-κB pathways. *Acta Pharmacol. Sin.* **2013**, *34*, 901–911, doi:10.1038/aps.2013.24.

59. Liu, T.; Li, C.; Sun, H.; Luo, T.; Tan, Y.; Tian, D.; Guo, Z. Curcumin inhibits monocyte chemoattractant protein-1 expression and enhances cholesterol efflux by suppressing the c-Jun N-terminal kinase pathway in macrophage. *Inflamm. Res. Off. J. Eur. Histamine Res. Soc.* ... [et al.]**2014**, *63*, 841–850, doi:10.1007/s00011-014-0758-9.

60. Ahn, J.; Lee, H.; Kim, S.; Ha, T. Curcumin-induced suppression of adipogenic differentiation is accompanied by activation of Wnt/beta-catenin signaling. *Am. J. Physiol. Cell Physiol.* **2010**, *298*, C1510-6, doi:10.1152/ajpcell.00369.2009.

61. Zhang, X.; Liu, J.; Pang, X.; Zhao, J.; Xu, S. Curcumin Suppresses Aldosterone-Induced CRP Generation in Rat Vascular Smooth Muscle Cells via Interfering with the ROS-ERK1/2 Signaling Pathway. *Evid. Based. Complement. Alternat. Med.* **2020**, *2020*, 3245653, doi:10.1155/2020/3245653.

62. Wu, T.; Xiang, Y.; Lv, Y.; Li, D.; Yu, L.; Guo, R. miR-590-3p mediates the protective effect of curcumin on injured endothelial
63. Ramaswami, G.; Chai, H.; Yao, Q.; Lin, P.H.; Lumsden, A.B.; Chen, C. Curcumin blocks homocysteine-induced endothelial dysfunction in porcine coronary arteries. J. Vasc. Surg. 2004, 40, 1216–1222, doi:https://doi.org/10.1016/j.vjs.2004.09.021

64. Montiel-Dávalos, A.; Silva Sánchez, G.J.; Huerta-García, E.; Rueda-Romero, C.; Soca Chafre, G.; Mitre-Aguilar, I.B.; Alfaro-Moreno, E.; Pedraza-Chaverri, J.; López-Marure, R. Curcumin inhibits activation induced by urban particulate material or titanium dioxide nanoparticles in primary human endothelial cells. PLoS One 2017, 12, e0188169, doi:10.1371/journal.pone.0188169.

65. Lee, S.E.; Park, H.R.; Jeon, S.; Han, D.; Park, Y.S. Curcumin Attenuates Acrolein-induced COX-2 Expression and Prostaglandin Production in Human Umbilical Vein Endothelial Cells. J. lipid Atheroscler. 2020, 9, 184–194, doi:10.12997/jla.2020.9.1.184.

66. Lee, H.-S.; Lee, M.-J.; Kim, H.; Choi, S.-K.; Kim, J.-E.; Moon, H.-I.; Park, W.-H. Curcumin inhibits TNFα-induced lectin-like oxidised LDL receptor-1 (LOX-1) expression and suppresses the inflammatory response in human umbilical vein endothelial cells (HUVECs) by an antioxidant mechanism. J. Enzyme Inhib. Med. Chem. 2010, 25, 720–729, doi:10.3109/14756360903555274.

67. Kim, D.-C.; Ku, S.-K.; Lee, W.; Bae, J.-S. Barrier protective activities of curcumin and its derivative. Inflamm. Res. Off. J. Eur. Histamine Res. Soc. ... et al. 2012, 61, 437–444, doi:10.1007/s00011-011-0430-6.

68. Kim, Y.S.; Ahn, Y.; Hong, M.H.; Joo, S.Y.; Kim, K.H.; Ohn, I.S.; Park, H.W.; Hong, Y.J.; Kim, J.H.; Kim, W.; et al. Curcumin attenuates inflammatory responses of TNF-alpha-stimulated human endothelial cells. J. Cardiovasc. Pharmacol. 2007, 50, 41–49, doi:10.1097/FJC.0b013e31805559b9.

69. Zhong, Y.; Feng, J.; Li, J.; Fan, Z. Curcumin prevents lipopolysaccharide-induced matrix metalloproteinase-2 activity via the Ras/MEK1/2 signaling pathway in rat vascular smooth muscle cells. Mol. Med. Rep. 2017, 16, 4315–4319, doi:10.3892/mmr.2017.7037.

70. Zhang, M.; Li, Y.; Xie, H.; Chen, J.; Liu, S. Curcumin inhibits proliferation, migration and neointimal formation of vascular smooth muscle via activating miR-22. Pharm. Biol. 2020, 58, 610–619, doi:10.1080/13880209.2020.1781904.

71. Yuan, H.-Y.; Kuang, S.-Y.; Zheng, X.; Ling, H.-Y.; Yang, Y.-B.; Yan, P.-K.; Li, K.; Liao, D.-F. Curcumin inhibits cellular cholesterol accumulation by regulating SREBP-1/caveolin-1 signaling pathway in vascular smooth muscle cells. Acta Pharmacol. Sin. 2008, 29, 555–563, doi:10.1111/j.1745-7254.2008.00783.x.

72. den Dekker, W.K.; Cheng, C.; Pasterkamp, G.; Duckers, H.J. Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis 2010, 209, 314–320, doi:https://doi.org/10.1016/j.atherosclerosis.2009.09.075.

73. Kim, K.-H.; Lee, E.N.; Park, J.K.; Lee, J.-R.; Kim, H.-S.; Lee, H.-W.; Lee, K.-S.; Yoon, S. Curcumin attenuates TNF-α-induced expression of intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and proinflammatory cytokines in human endometriotic stromal cells. Inflamm. Res. Off. J. Eur. Histamine Res. Soc. ... et al. 2012, 26, 1037–1047, doi:10.1002/ptr.3694.

74. Latz, E.; Xiao, T.S.; Stutz, A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 2013, 13, 397–411, doi:10.1038/nri3452.

75. Tian, K.; Ogura, S.; Little, P.J.; Xu, S.; Sawamura, T. Targeting LOX-1 in atherosclerosis and vasculopathy: current knowledge and future perspectives. Ann. N. Y. Acad. Sci. 2019, 1443, 34–53, doi:https://doi.org/10.1111/nyas.13984.

76. Min, K.; Um, H.J.; Cho, K.-H.; Kwon, T.K. Curcumin inhibits oxLDL-induced CD36 expression and foam cell formation through the inhibition of p38 MAPK phosphorylation. Food Chem. Toxicol. an Int. J. Publ. Br. Ind. Biol. Res. Assoc. 2013, 58, 77–85, doi:10.1016/j.fct.2013.04.008.

77. Tontonoz, P.; Nagy, L.; Alvarez, J.G.A.; Thomazy, V.A.; Evans, R.M. PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL. Cell 1998, 93, 241–252, doi:https://doi.org/10.1016/S0092-8674(00)81575-5.

78. Chistiakov, D.A.; Bobryshev, Y. V; Orekhov, A.N. Macrophage-mediated cholesterol handling in atherosclerosis. J. Cell. Mol. Med. 2016, 20, 17–28, doi:https://doi.org/10.1111/jcmm.12689.

79. Makowski, L.; Brittingham, K.C.; Reynolds, J.M.; Suttle, J.; Hotamisligil, G.S. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J. Biol. Chem. 2005, 280, 12888–12895.
80. Wessel, J.; Topol, EJ.; Ji, M.; Meyer, J.; McCarthy, JJ. Replication of the association between the thrombospondin-4 A387P polymorphism and myocardial infarction, Am Heart J 147 2004:905-909

81. Changal, K.H.; Khan, M.S.; Bashir, R.; Sheikh, M.A. Curcumin Preparations Can Improve Flow-Mediated Dilation and Endothelial Function: A Meta-Analysis. Complement. Med. Res. 2020, 27, 272–281.

82. Li, X.; Lu, Y.; Sun, Y.; Zhang, Q. Effect of curcumin on permeability of coronary artery and expression of related proteins in rat coronary atherosclerosis heart disease model. Int. J. Clin. Exp. Pathol. 2015.

83. Majeed, M.L.; Ghafil, F.A.; Fatima, G.; Hadi, N.R.; Mahdi, H.F. Anti-Atherosclerotic and Anti-Inflammatory Effects of Curcumin on Hypercholesterolemic Male Rabbits. Indian J. Clin. Biochem. 2021, 36, 74–80, doi:10.1007/s12291-019-00858-5.

84. Helli, B.; Gerami, H.; Kavianpour, M.; Heybar, H.; Hosseini, S.K.; Haghighian, H.K. Curcumin Nanomicelle Improves Lipid Profile, Stress Oxidative Factors and Inflammatory Markers in Patients Undergoing Coronary Elective Angioplasty: A Randomized Clinical Trial. Endocr. Metab. Immune Disord. Drug Targets 2021.

85. Li, L.; Zhang, X.; Pi, C.; Yang, H.; Zheng, X.; Zhao, L.; Wei, Y. Review of Curcumin Physicochemical Targeting Delivery System. Int. J. Nanomedicine 2020, 15, 9799–9821, doi:10.2147/IJN.S276201.

86. Pechanova, O.; Dayar, E.; Cebova, M. Therapeutic Potential of Polyphenols-Loaded Polymeric Nanoparticles in Cardiovascular System. Molecules 2020, 25, doi:10.3390/molecules25153322.